US4317882A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Production of plasminogen activator
Assignee: Asahi Kasei Corp
•
Filing: 1980-04-25
•
Granted: 1982-03-02
•
Expires: 2000-04-25
Abstract
Abstract A plasminogen activator having a molecular weight of 45,000 to 68,000 is formed as a single fraction in the cells of human kidney or lung, and is separated and recovered with good efficiency without reducing its molecular weight. The pH of a solution to be contacted with said cells and the concentration of dissolved oxygen should be maintained within suitable ranges in order to form the plasminogen activator having a molecular weight of 45,000 to 68,000 as a single fraction. Furthermore, by properly adjusting the residence time of the solution with the cells, the activator can be formed over a long period of more than 40 days. To separate the activator, the pH of the solution in the separating step is maintained preferably at 4 to 12. By causing a metal chelating agent to be present in the solution in the separating step, the plasminogen activator can be obtained without reducing its molecular weight.
Inventors
- 👤 Sadayuki Horiguchi
- 👤 Akio Hasegawa
- 👤 Mitsuru Shibukawa
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 13:42
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6456; C12N9/6462; C12Y; C12Y304/00; C12Y304/21; C12Y304/21073; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/818
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
109 words
A process for producing plasminogen activator having a molecular weight in the range from about 45,000 to 68,000, which comprises: (1) contacting a solution containing a carbon source and a nitrogen source with cells derived from human kidneys or lungs and having the ability to produce a plasminogen activator while maintaining the pH of said solution in a range from about 6 to 9 and the concentration of dissolved oxygen in said solution at a level of at least 30% of the saturation concentration of dissolved oxygen; and (2) separating the resulting plasminogen activator from the solution while maintaining the pH in a range from about 4 to 12.
Claim 2
Dependent Claim
109 words
A process for producing plasminogen activator having a molecular weight in the range from about 45,000 to 68,000, which comprises: (1) contacting a solution containing a carbon source and a nitrogen source with cells derived from human kidneys or lungs and having the ability to produce a plasminogen activator while maintaining the pH of said solution in a range from about 6 to 9 and the concentration of dissolved oxygen in said solution at a level of at least 30% of the saturation concentration of dissolved oxygen; and (2) separating the resulting plasminogen activator from the solution while maintaining the pH in a range from about 4 to 12.
Claim 3
Dependent Claim
50 words
A process as in claim 1, wherein by adjusting the residence time of solution with the cells to not more than 30 days, at least 95% of the plasminogen activator formed over a period of at least 60 days has a molecular weight in the range of 45,000 to 68,000.
Claim 4
Dependent Claim
50 words
A process as in claim 1, wherein by adjusting the residence time of solution with the cells to not more than 10 days, the plasminogen activator formed over a period of at least 40 days has a molecular weight in the range of 45,000 to 68,000 as a single fraction.
Claim 5
Dependent Claim
25 words
A process as in claim 1, 2 or 3, wherein step (2) is carried out in the presence of at least one metal chelating agent.
Claim 6
Dependent Claim
26 words
The process of claim 4, wherein the concentration of said metal chelating agent in the solution is at least 0.1 millimole per liter of the solution.
Claim 7
Dependent Claim
26 words
The process of claim 4, wherein the concentration of said metal chelating agent in the solution is at least 0.3 millimole per liter of the solution.
Claim 8
Dependent Claim
27 words
A process as in claim 4, wherein said chelating agent is at least one member selected from the group consisting of ortho-phenanthroline, trans-1,2-diaminocyclohexanetetraacetic acid and ethylenediaminetetraacetic acid.
Claim 9
Dependent Claim
27 words
A process as in claim 5, wherein said chelating agent is at least one member selected from the group consisting of ortho-phenanthroline, trans-1,2-diaminocyclohexanetetraacetic acid and ethylenediaminetetraacetic acid.
Claim 10
Dependent Claim
27 words
A process as in claim 6, wherein said chelating agent is at least one member selected from the group consisting of ortho-phenanthroline, trans-1,2-diaminocyclohexanetetraacetic acid and ethylenediaminetetraacetic acid.
Claim 11
Dependent Claim
25 words
A process as in claim 1, 2 or 3, wherein step (1) is carried out at a temperature of from about 15° to 45° C.
References Cited (Backward Citations)
US3873423A
Cited
US3930944A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-03-01 | 1985-08-31 | 1986-03-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-03-01 | 1989-08-31 | 1990-03-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-03-01 | 1993-08-31 | 1994-03-02 | $7700.00 | Window Closed / Lapsed |